Fulgent Genetics Inc Revenue Growth Rates (FLGT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Fulgent Genetics Inc   (NASDAQ: FLGT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

FLGT's Revenue Growth by Quarter and Year

Fulgent Genetics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/FLGT/growth
https://api.csimarket.com/api/v1/companies/FLGT/fundamentals
https://api.csimarket.com/api/v1/companies/FLGT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
FLGT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 90.41
2nd Quarter June 85.39
1st Quarter March 70.49
FY 246.29

FLGTs Annual Revenue
Fulgent Genetics Inc 's Revenue in the fiscal year 2025 $ 321.88 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2024 $ 283.22 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2023 $ 288.46 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2022 $ 618.97 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2021 $ 992.58 millions




FLGT Revenue third quarter 2026 Y/Y Growth Comment
Fulgent Genetics Inc reported Revenue growth of 8.26% year on year in the third quarter 2026, to $ 90.41 millions, this is lower than Fulgent Genetics Inc 's recent average Revenue surge of 245.49%.

Looking into third quarter 2026 results within Medical Laboratories industry 21 other companies have achieved higher Revenue growth. While Fulgent Genetics Inc ' s Revenue increase of 8.26% ranks overall at the positon no. 2259 in the third quarter 2026.


FLGT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.26 %
2nd Quarter June 4.85 %
1st Quarter March -3.9 %
FY   -

Financial Statements
Fulgent Genetics Inc 's third quarter 2026 Revenue $ 90.41 millions FLGT's Income Statement
Fulgent Genetics Inc 's third quarter 2025 Revenue $ 83.51 millions Quarterly FLGT's Income Statement


FLGT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.88 %
2nd Quarter June 21.14 %
1st Quarter March -15.66 %
FY (Year on Year)   -


Back to FLGT Growth rate Comparisons >> Back to FLGT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #335
Overall #2259

Revenue Y/Y Growth Statistics
High Average Low
4536 % 245.49 % -79.34 %
(Mar 31 2021)   (Jun 30 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #335
Overall #2259
Revenue Y/Y Growth Statistics
High Average Low
4536 % 245.49 % -79.34 %
(Mar 31 2021)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Fulgent Genetics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
489.15 % 21.51 % -60.86 %
(Sep 30 2020)  


FLGT's III. Quarter Q/Q Revenue Comment
Fulgent Genetics Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.88% quarter on quarter, to $ 90.41 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 2.54% growth in the III. Quarter a year ago

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Fulgent Genetics Inc 's Revenue growth quarter on quarter, overall rank is 492.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #97
Overall #492
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #97
Overall #492
Revenue Q/Q Growth Statistics
High Average Low
489.15 % 21.51 % -60.86 %
(Sep 30 2020)  


FLGT's III. Quarter Q/Q Revenue Comment
Fulgent Genetics Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.88% quarter on quarter, to $ 90.41 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.54% in the III. Quarter a year ago.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Fulgent Genetics Inc 's Revenue growth quarter on quarter, overall rank is 492.


Fulgent Genetics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 329.87
Y / Y Revenue Growth (TTM) 4.34 %
Year on Year Revenue Growth Overall Ranking # 2083
Seqeuential Revenue Change (TTM) 2.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 2217


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Fulgent Genetics Inc 's cumulative twelve months Revenue were $ 330 millions, company would post below average annual Revenue growth of 2.14% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Fulgent Genetics Inc 's Revenue growth from the 85.39% growth in Jun 30 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1992 to 2083.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 312
Overall # 2083

Revenue TTM Y/Y Growth Statistics
High Average Low
2115.31 %
 172.43 %
-66.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 326
S&P 500 # 2217
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Fulgent Genetics Inc 's cumulative twelve months Revenue were $ 330 millions, company would post below average annual Revenue growth of -66.81% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Fulgent Genetics Inc 's Revenue growth from the 85.39% growth in Jun 30 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1992 to 2083.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 312
Overall # 2083

Revenue TTM Y/Y Growth Statistics
High Average Low
2115.31 %
172.43 %
-66.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 326
S&P 500 # 2217




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FLGT's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions


About Fulgent Genetics Inc Revenue Growth Rates (FLGT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Fulgent Genetics Inc (CIK 1674930).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-449803
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Fulgent Genetics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.